Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24147096 | 0.84 | TSHR (0.46) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL10567833 | 0.84 | MEN1 (0.56) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL31231920 | 0.84 | MEN1 (0.56) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL24265378 | 0.83 | MAPT (0.57) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL4076876 | 0.80 | MEN1 (0.53) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL20038685 | 0.80 | TSHR (0.42) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL20048798 | 0.80 | TSHR (0.42) | MAPTALDH1A1MEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL3184764 | 0.78 | MEN1 (0.51) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL9187556 | 0.78 | MEN1 (0.61) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL23208083 | 0.78 | MAPT (0.42) | MAPTALDH1A1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119894509-A | Sodium channel blocking compounds, derivatives thereof, and methods of use thereof | 拉堤果生物医疗股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2023151118-A1 | STYRENE-MALEIC ACID COPOLYMERIZED MACROMOLECULAR REACTIVE DYE AND PREPARATION METHOD THEREFOR | 大连理工大学 | 2023-08-17 | — | — | WO | disclosed |
| WO-2022263604-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2022-12-22 | — | — | WO | disclosed |
| EP-3988549-A1 | MACROCYCLES WITH HETEROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2021214037-A1 | FLOW CELLS | ILLUMINA CAMBRIDGE LIMITED (GB) | 2021-10-28 | — | — | WO | disclosed |
| WO-2018045969-A1 | COMPOUND FOR ACTIVATING ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE | 法玛科技顾问股份有限公司 | 2018-03-15 | — | — | WO | disclosed |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170174639-A1 | EIS INHIBITORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2017-06-22 | — | — | US | disclosed |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | THE UNITED STATES OF AMERICA AS REPRESENTED BY SECRETARY DEPT OF HEALTH AND HUMAN SERVICE (US) | 2017-05-25 | — | — | US | disclosed |
| EP-1041986-A4 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2001-03-21 | — | — | EP | disclosed |
| US-6156741-A | Therapeutic substituted guanidines | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-12-05 | — | — | US | disclosed |
| US-6153604-A | Therapeutic substituted guanidines | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| US-6147063-A | NEUROTOXICITY | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-1041986-A1 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999018962-A1 | PHARMACEUTICALLY ACTIVE COMPOUND AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| CN-1126434-A | Therapeutic substituted guanidines | CAMBRIDGE NEUROSCIENCE INC (US) | 1996-07-10 | — | — | CN | disclosed |
| EP-0705100-A4 | THERAPEUTIC SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE INC (US) | 1996-05-29 | — | — | EP | disclosed |
| EP-0705100-A1 | THERAPEUTIC SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1996-04-10 | — | — | EP | disclosed |
| WO-1994027591-A1 | THERAPEUTIC SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | MAPT 350/4885ALDH1A1 4099/4885MEN1 728/4885 |
| US-20170174639-A1 | EIS INHIBITORS | ABCC1, ATP5ME, ABCG2 | MAPT 3708/4885ALDH1A1 819/4885MEN1 3949/4885 |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | MAPT 4163/4885ALDH1A1 1049/4885MEN1 3035/4885 |
| US-20170144984-A1 | MODULATORS OF THE RELAXIN RECEPTOR 1 | RXFP1, RXFP2, RXFP3 | MAPT 4541/4885ALDH1A1 2561/4885MEN1 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.